Claims for Patent: 8,613,949

Summary for Patent: 8,613,949

Title:	Galenical formulations of organic compounds
Abstract:	The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Amlodipine, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 60% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component (b) of 50% or more after 20 minutes, and 70% or more after 30 minutes at pH 2, said pharmaceutical oral fixed dose combination being bioequivalent, or close to reaching bioequivalence, to a free dose combination of Aliskiren and Amlodipine.
Inventor(s):	Valazza; Stephen (Matawan, NJ), Wagner; Robert F (Hillsborough, NJ), Vippagunta; Sudha (Morris Plains, NJ)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/063,955
Patent Claims:	1. A pharmaceutical oral fixed dose combination in the form of a monolayer tablet, comprising a) a therapeutically effective amount ranging from 10 to 45% by weight based on the total weight of the pharmaceutical oral fixed dose combination of aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount ranging from 0.5 to 5% of amlodipine, or a pharmaceutically acceptable salt thereof, c) a disintegrant in an amount of 2 to 15% by weight of the tablet, d) a diluent in an amount of 1 to 60% by weight, e) a binder in an amount of 0.1 to 20% by weight, f) a lubricant in an amount of 0.1 to 5% by weight, and g) a glidant in an amount of 0.5 to 5% by weight; wherein in each case not mentioned otherwise the percentage of weight being defined prior to any optional film coating, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 60% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component (b) of 50% or more after 20 minutes, and 70% or more after 30 minutes at pH 2. 2. The pharmaceutical oral fixed dose combination according to claim 1, wherein component (a) is in the form of a granulate obtainable by wet granulation. 3. The pharmaceutical oral fixed dose combination according to claim 1, wherein component (b) is in the form of a granulate obtainable by roller compaction. 4. The pharmaceutical oral fixed dose combination according to claim 1, wherein component (a) is present in an amount ranging from 75 to 300 mg, of the free base per unit dosage form. 5. The pharmaceutical oral fixed dose combination according to claim 1, wherein component (b) is present in an amount ranging from 1 to 20 mg, per unit dosage form. 6. A method for the preparation of a pharmaceutical oral fixed dose combination according to claim 1, said method comprising the steps of (1) granulating component (a) with at least one pharmaceutically acceptable additive optionally in the presence of a granulation liquid to form an alikiren granulate: (2) granulating component (b) with at least one pharmaceutically acceptable additive to form an amlodipine granulate; (3) optionally drying resulting respective granulates; (4) sieving respective granulates; (5) optionally mixing the respectives granulates with outer phase excipients; (6) mixing repective granulates; (7) screening the material from step (6); (8) optionally, blending the obtained sieved material from (7) together with further pharmaceutically acceptable additives; (9) compressing the blend from (8) to form a monolayer tablet and (10) optionally film coating the obtained monolayer tablet. 7. A pharmaceutical oral fixed dose combination according to claim 1, wherein aliskiren is in the form of the hemi-fumarate salt thereof. 8. A pharmaceutical oral fixed dose combination according to claim 1, wherein amlodipine is in the form of the besylate salt thereof. 9. The pharmaceutical oral fixed dose combination according to claim 4, wherein component (a) is present in an amount of 150 mg or 300 mg, of the free base per unit dosage form. 10. The pharmaceutical oral fixed dose combination according to claim 5, wherein component (b) is present in an amount of 5 mg or 10 mg, per unit dosage form. 11. The pharmaceutical oral fixed dose combination according to claim 1, comprising a) a therapeutically effective amount ranging from 20 to 35% by weight based on the total weight of the pharmaceutical oral fixed dose combination of aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount ranging from 0.5 to 3% of amlodipine, or a pharmaceutically acceptable salt thereof, c) a disintegrant in an amount of 2 to 12% by weight of the tablet, d) a diluent in an amount of 10 to 55% by weight, e) a binder in an amount of 0.5 to 15% by weight, f) a lubricant in an amount of 0.5 to 3% by weight, and g) a glidant in an amount of 0.5 to 5% by weight wherein in each case where not mentioned otherwise the percentage of weight being defined prior to any optional film coating. 12. The pharmaceutical oral fixed dose combination according to claims 1, 9 or 10, further comprising a film coating. 13. The pharmaceutical oral fixed dose combination according to claim 12, wherein the film coating material is a polymeric film coating material selected from hydroxypropylmethyl cellulose, polyethylene glycol, talc, and colorant. 14. The pharmaceutical oral fixed dose combination according to claim 1 or 11 wherein the disintegrant is crospovidone, the diluent is microcrystalline cellulose, the binder is povidone, the lubricant is magnesium stearate and the glidant is colloidal silicon dioxide.